. "CZ - \u010Cesk\u00E1 republika" . . . "The first 1,000 liver transplantations in IKEM"@en . "Prvn\u00EDch 1 000 transplantac\u00ED jater v IKEM" . "Herman, Ale\u0161" . "67" . . "Ha\u010Dkajlo, David" . . . "RIV/00023001:_____/13:00058696!RIV14-MZ0-00023001" . . . . . "Prvn\u00EDch 1 000 transplantac\u00ED jater v IKEM"@cs . . . "\u0160pi\u010D\u00E1k, Julius" . "Prvn\u00EDch 1 000 transplantac\u00ED jater v IKEM" . "Honsov\u00E1, Eva" . . "100842" . "Trune\u010Dka, Pavel" . . "Oliverius, Martin" . "Ku\u010Dera, Milo\u0161" . "5" . "Prvn\u00EDch 1 000 transplantac\u00ED jater v IKEM"@cs . . . . "Gastroenterologie a hepatologie" . . "Hejlov\u00E1, Irena" . "Ro\u010De\u0148, Milan" . "Fron\u011Bk, Ji\u0159\u00ED" . . . . "[C76A7EB52C6D]" . "Gottfriedov\u00E1, Halima" . . "Pokorn\u00E1, Eva" . . "8"^^ . . "1804-7874" . . "20"^^ . . . . "N" . "20"^^ . "http://www.csgh.info/dwnld/gh_2013_5_399_406.pdf" . "Jane\u010Dkov\u00E1, Lucie" . "Fra\u0148kov\u00E1, So\u0148a" . "immunosuppression, indication, survival, liver transplantation"@en . "One thousand orthotopic liver transplantations (LTx) were performed in the Transplant Centre of the Institute of Clinical and Experimental Medicine in Prague in 950 transplant recipients, 559 men and 391 females, aged 0.4-74 years during the period between April 2, 1995 and August 13, 2013. At the beginning of the programme, the average age of the recipients was 41, and 48.8 in 2012 (including child recipients). At the beginning, the average MELD/PELD score was 18.5, and this decreased to 16.3 in 2012. During the same period the mean waiting time of the listed patients increased from 42.3 to 164.9 days. Out of the total, 28 LTx were performed simultaneously with a kidney transplantation, and two with a pancreatic islets transplantation. The most frequent chronic liver disease in the patients listed for the first LTx was alcoholic liver cirrhosis in 25.4% recipients, hepatitis C cirrhosis in 13.5%, and primary sclerosing cholangitis in 11% of patients. An acute form of Wilson's disease in 37% and a fulminant course of hepatitis B in 18.5% of patients were the most prevalent indications among the urgently listed patients. Initial immunosuppression was provided based on various combinations; the main medicine being calcineurine inhibitors (99.5%) of which Cyclosporin A was used in 266 and Tacrolimus in 729 recipients. One-year survival of recipients (Kaplan-Meier method) was 89.8%, five-year 83.1%, 10-year 75.5%, and 15-year 65.2%, and the graft survival was 86.6%, 79.4%, 71.0%, and 60.2 % respectively. The best patient and graft survival rate was achieved in patients transplanted for biliary cirrhosis and was significantly better than in any other indication group (p < 0.027). The main cause of mortality among transplant recipients during the first post-transplant year (89 cases) was sepsis (20 patients) and de novo tumours in the following years (104 cases)."@en . "Janou\u0161ek, Libor" . "V obdob\u00ED od 2. dubna 1995 do 13. srpna 2013 bylo v Transplantcentru IKEM provedeno 1 000 ortotopick\u00FDch transplantac\u00ED jater u 950 p\u0159\u00EDjemc\u016F, 559 mu\u017E\u016F a 391 \u017Een, ve v\u011Bku 0,4-74 let. Pr\u016Fm\u011Brn\u00E9 st\u00E1\u0159\u00ED pacient\u016F v dob\u011B zah\u00E1jen\u00ED programu bylo 41 let, v roce 2012 (v\u010Detn\u011B d\u011Btsk\u00FDch p\u0159\u00EDjemc\u016F) 48,8 let. Pr\u016Fm\u011Brn\u00E9 MELD/PELD sk\u00F3re v dob\u011B zah\u00E1jen\u00ED programu \u010Dinilo 18,5; v roce 2012 16,3. Pr\u016Fm\u011Brn\u00E1 \u010Dekac\u00ED doba na listin\u011B se ve sledovan\u00E9m obdob\u00ED zv\u00FD\u0161ila ze 42,3 dn\u016F na 164,9 dn\u016F. Z uveden\u00E9ho po\u010Dtu bylo kombinovan\u00FDch transplantac\u00ED j\u00E1tra s ledvinou 28 p\u0159\u00EDpad\u016F, j\u00E1tra spole\u010Dn\u011B s ostr\u016Fvky pankreatu dva p\u0159\u00EDpady. Vedouc\u00ED indikac\u00ED k prvn\u00ED transplantaci jater pro chronick\u00E1 onemocn\u011Bn\u00ED byla alkoholick\u00E1 jatern\u00ED cirh\u00F3za ve 25,4 %, chronick\u00E1 hepatitida C ve 13,5 % a prim\u00E1rn\u00ED sklerozuj\u00EDc\u00ED cholangitida v 11,0 %. Nej\u010Dast\u011Bj\u0161\u00ED indikac\u00ED k urgentn\u00ED transplantaci byla akutn\u00ED forma Wilsonovy choroby jater ve 37 % a fulminantn\u00ED pr\u016Fb\u011Bh virov\u00E9 hepatitidy B v 18,5 %. Inici\u00E1ln\u00ED imunosuprese byla zaji\u0161t\u011Bna r\u016Fzn\u00FDmi kombinacemi, kdy z\u00E1kladn\u00EDm l\u00E9kem byl kalcineurinov\u00FD inhibitor (99,5 %), z toho cyklosporin A u 266 p\u0159\u00EDjemc\u016F, takrolimus u 729 p\u0159\u00EDjemc\u016F. Za cel\u00E9 obdob\u00ED trv\u00E1n\u00ED programu p\u0159e\u017E\u00EDv\u00E1 jeden rok po transplantaci 89,8 %, p\u011Bt let 83,1 %, 10 let 75,5 % a 15 let 65,2 % p\u0159\u00EDjemc\u016F, resp. 86,6 %, 79,4 %, 71,0 % a 60,2 % \u0161t\u011Bp\u016F (Kaplan- Meierova metoda). Nejlep\u0161\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F i \u0161t\u011Bp\u016F bylo dosa\u017Eeno u pacient\u016F s bili\u00E1rn\u00EDmi cirh\u00F3zami, v\u00FDznamn\u011B lep\u0161\u00ED oproti ostatn\u00EDm skupin\u00E1m (p < 0,027). Hlavn\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED v prvn\u00EDm roce po transplantaci (celkem 89 pacient\u016F) byla sepse (20 p\u0159\u00EDpad\u016F), v n\u00E1sleduj\u00EDc\u00EDch letech (104 p\u0159\u00EDpad\u016F) n\u00E1dory de novo po transplantaci (19 p\u0159\u00EDjemc\u016F). Transplantace jater je velmi \u00FA\u010Dinnou l\u00E9\u010Debnou metodou, kter\u00E1 pacient\u016Fm s \u017Eivot ohro\u017Euj\u00EDc\u00EDm jatern\u00EDm onemocn\u011Bn\u00EDm z\u00E1sadn\u00EDm zp\u016Fsobem prodlou\u017E\u00ED \u017Eivot v\u010Detn\u011B mo\u017Enosti pln\u00E9ho \u017Eivotn\u00EDho zapojen\u00ED." . . . "Kieslichov\u00E1, Eva" . "Peregrin, Jan" . "\u0160perl, Jan" . . . "Drastich, Pavel" . . "L\u00E1nsk\u00E1, V\u011Bra" . . "The first 1,000 liver transplantations in IKEM"@en . "RIV/00023001:_____/13:00058696" . . "V obdob\u00ED od 2. dubna 1995 do 13. srpna 2013 bylo v Transplantcentru IKEM provedeno 1 000 ortotopick\u00FDch transplantac\u00ED jater u 950 p\u0159\u00EDjemc\u016F, 559 mu\u017E\u016F a 391 \u017Een, ve v\u011Bku 0,4-74 let. Pr\u016Fm\u011Brn\u00E9 st\u00E1\u0159\u00ED pacient\u016F v dob\u011B zah\u00E1jen\u00ED programu bylo 41 let, v roce 2012 (v\u010Detn\u011B d\u011Btsk\u00FDch p\u0159\u00EDjemc\u016F) 48,8 let. Pr\u016Fm\u011Brn\u00E9 MELD/PELD sk\u00F3re v dob\u011B zah\u00E1jen\u00ED programu \u010Dinilo 18,5; v roce 2012 16,3. Pr\u016Fm\u011Brn\u00E1 \u010Dekac\u00ED doba na listin\u011B se ve sledovan\u00E9m obdob\u00ED zv\u00FD\u0161ila ze 42,3 dn\u016F na 164,9 dn\u016F. Z uveden\u00E9ho po\u010Dtu bylo kombinovan\u00FDch transplantac\u00ED j\u00E1tra s ledvinou 28 p\u0159\u00EDpad\u016F, j\u00E1tra spole\u010Dn\u011B s ostr\u016Fvky pankreatu dva p\u0159\u00EDpady. Vedouc\u00ED indikac\u00ED k prvn\u00ED transplantaci jater pro chronick\u00E1 onemocn\u011Bn\u00ED byla alkoholick\u00E1 jatern\u00ED cirh\u00F3za ve 25,4 %, chronick\u00E1 hepatitida C ve 13,5 % a prim\u00E1rn\u00ED sklerozuj\u00EDc\u00ED cholangitida v 11,0 %. Nej\u010Dast\u011Bj\u0161\u00ED indikac\u00ED k urgentn\u00ED transplantaci byla akutn\u00ED forma Wilsonovy choroby jater ve 37 % a fulminantn\u00ED pr\u016Fb\u011Bh virov\u00E9 hepatitidy B v 18,5 %. Inici\u00E1ln\u00ED imunosuprese byla zaji\u0161t\u011Bna r\u016Fzn\u00FDmi kombinacemi, kdy z\u00E1kladn\u00EDm l\u00E9kem byl kalcineurinov\u00FD inhibitor (99,5 %), z toho cyklosporin A u 266 p\u0159\u00EDjemc\u016F, takrolimus u 729 p\u0159\u00EDjemc\u016F. Za cel\u00E9 obdob\u00ED trv\u00E1n\u00ED programu p\u0159e\u017E\u00EDv\u00E1 jeden rok po transplantaci 89,8 %, p\u011Bt let 83,1 %, 10 let 75,5 % a 15 let 65,2 % p\u0159\u00EDjemc\u016F, resp. 86,6 %, 79,4 %, 71,0 % a 60,2 % \u0161t\u011Bp\u016F (Kaplan- Meierova metoda). Nejlep\u0161\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F i \u0161t\u011Bp\u016F bylo dosa\u017Eeno u pacient\u016F s bili\u00E1rn\u00EDmi cirh\u00F3zami, v\u00FDznamn\u011B lep\u0161\u00ED oproti ostatn\u00EDm skupin\u00E1m (p < 0,027). Hlavn\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED v prvn\u00EDm roce po transplantaci (celkem 89 pacient\u016F) byla sepse (20 p\u0159\u00EDpad\u016F), v n\u00E1sleduj\u00EDc\u00EDch letech (104 p\u0159\u00EDpad\u016F) n\u00E1dory de novo po transplantaci (19 p\u0159\u00EDjemc\u016F). Transplantace jater je velmi \u00FA\u010Dinnou l\u00E9\u010Debnou metodou, kter\u00E1 pacient\u016Fm s \u017Eivot ohro\u017Euj\u00EDc\u00EDm jatern\u00EDm onemocn\u011Bn\u00EDm z\u00E1sadn\u00EDm zp\u016Fsobem prodlou\u017E\u00ED \u017Eivot v\u010Detn\u011B mo\u017Enosti pln\u00E9ho \u017Eivotn\u00EDho zapojen\u00ED."@cs .